Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are a heterogeneous group of diseases corresponding to necrotising inflammation of small vessels with a wide range of clinical presentations. ANCA disease process is characterized by necrotizing inflammation of small vessels, the relative paucity of immune deposits and an association with detectable circulating ANCAs. ANCA has been divided into three subtypes, granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA, formerly Churg-Strauss syndrome). The symptoms of ANCA include bloody sputum, bloody nose nasal discharge, fatigue, fever, hearing problems or hearing loss, nasal ulcerations, joint pain, shortness of breath and weight loss. The treatment of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides include a monoclonal antibody namely, rituximab.
Some of the drug candidates in the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis pipeline include, but are not limited to, Avacopan, and Dalazatide. Some of the companies having drugs in the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis pipeline include Bristol-Myers Squibb Company, ChemoCentryx, Inc. GlaxoSmithKline Plc and Coherus BioSciences, Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.